Abstract
In this chapter, the fundamentals of pharmacovigilance are outlined with a particular emphasis on the role of healthcare professionals in reporting adverse drug reactions (ADRs). It also explains why pharmacovigilance is specifically important regarding biological medicinal products (biologicals).
Chapter PDF
References
Belton, K. J. and the European Pharmacovigilance Group (1997). Attitude Survey of Adverse Drug-Reaction Reporting by Health Care Professionals across the European Union. European Journal of Pharmacology 52: 423-427.
Alvarez-Requejo, A., Carvajal, A., Bégaud, B., Moride, Y., Vega, T., Martín Arias, L.H. (1998). Under-Reporting of Adverse Drug Reactions: Estimate Based on a Spontaneous Reporting Scheme and a Sentinel System. European Journal of Clinical Pharmacology 54: 483-488.
Arnaiz, J. A., Carné, X., Riba, N., Codina, C., Ribas, J., Trilla, A. (2001). The Use of Evidence in Pharmacovigilance – Case Reports as the Reference Source for Drug Withdrawals. European Journal of Clinical Pharmacology 57: 89-91.
Calvo, B., Zuňiga, L. (2014). EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars. Drug Safety 37: 9-18.
Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Schellekens, H., Leufkens, H. C. (2011). Today’s Challenges in Pharmacovigilance: What Can We Learn from Epoetins? Drug Safety 34(4): 273-287.
Eichler, H. G., Pignatti, F., Flamion, B., Leufkens, H., Breckenrige, A. (2008). Balancing Early Market Access to New Drugs with the Need for Benefit/Risk Data: A Mounting Dilemma. Nature Reviews Drug Discovery 7: 818-826.
Giezen, T. J., Straus, S. M. J. M. (2012). Pharmacovigilance of Biosimilars: Challenges and Possible Solutions. Generics and Biosimilars Initiative Journal 1 (3-4): 118-119.
Inácio, P., Airaksinen, M., Cavaco, A. (2015). Language Does Not Come “in Boxes”: Assessing Discrepancies between Adverse Drug Reactions Spontaneous Reporting and MedDRA ® Codes in European Portuguese. Research in Social and Administrative Pharmacy 11: 664-674.
Johnson, C.L., Hutchinson, J. A. (2015). Pharmacovigilance in Europe. Transplantation 99(8): 1542-1543.
Klein, K., Scholl, J. H. G., Vermeer, N. S., Broekmans, A. W., Van Puijenbroek, E. P., De Bruin, M. L., Stolk, P. (2016). Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports. Drug Safety 39: 185-192.
Kumar, A., Khan, H. (2015). Signal Detection and Their Assessment. In Pharmacovigilance. Open Pharmaceutical Science Journal 3: 66-73.
Pal, S. N., Duncombe, C., Falzon, D., Olsson, S. (2013). WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems. Drug Safety 36: 75-81
Vermeer, N. S., Straus, S. M. J. M., Mantel-Teeuwisse, A. K., Domergue, F., Egberts, T. C. G., Leufkens, H. G. M., De Bruin, M. L. (2013). Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases. Drug Safety 36: 617-625.
WHO (2004). Pharmacovigilance: Ensuring the Safe Use of Medicines. WHO Policy Perspectives on Medicines 9.
WHO (2016). WHO Education Guidelines. Last accessed 26.11.2016: http://whoeducationguidelines.org/content/1-definition-and-list-health-professionals
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2017 The Author(s)
About this chapter
Cite this chapter
Kaeding, M., Schmälter, J., Klika, C. (2017). Pharmacovigilance. In: Pharmacovigilance in the European Union. Springer, Wiesbaden. https://doi.org/10.1007/978-3-658-17276-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-658-17276-3_2
Published:
Publisher Name: Springer, Wiesbaden
Print ISBN: 978-3-658-17275-6
Online ISBN: 978-3-658-17276-3
eBook Packages: Political Science and International StudiesPolitical Science and International Studies (R0)